Spruce Biosciences (NASDAQ: SPRB) net income
Spruce Biosciences reported a net loss of $39.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $53.0m. Earnings per share were −$50.83.
Spruce Biosciences's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$39.0m | — | — | −$50.83 |
| 2024 | −$53.0m | — | −1,079.9% | −$1.29 |
| 2023 | −$47.9m | — | −475.0% | −$1.24 |
| 2022 | −$46.2m | — | — | −$1.96 |
| 2021 | −$42.3m | — | — | −$1.81 |
| 2020 | −$29.5m | — | — | — |
| 2019 | −$13.1m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Spruce Biosciences net income compared with its sector
By net income for its latest fiscal year, Spruce Biosciences ranks 239th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 237th | Lifecore Biomedical | −$38.7m | −30.0% |
| 238th | RxSight | −$38.9m | −29.0% |
| 239th | Spruce Biosciences | −$39.0m | — |
| 240th | TriSalus Life Sciences | −$39.2m | −86.9% |
| 241st | Elicio Therapeutics | −$39.6m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Spruce Biosciences
- How much did Spruce Biosciences earn in fiscal 2025?
- Spruce Biosciences reported a net loss of $39.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $53.0m.
- What are the earnings per share of Spruce Biosciences?
- They were −$50.83 in fiscal 2025, compared with −$1.29 in fiscal 2024.
- Where does Spruce Biosciences rank in its sector by net income?
- It ranks 239th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Spruce Biosciences come from?
- From the annual report (Form 10-K) that Spruce Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Spruce Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Spruce Biosciences: the Spruce Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.